Your browser doesn't support javascript.
loading
Symmetric signal transduction and negative allosteric modulation of heterodimeric mGlu1/5 receptors.
Werthmann, Ruth C; Tzouros, Manuel; Lamerz, Jens; Augustin, Angélique; Fritzius, Thorsten; Trovò, Luca; Stawarski, Michal; Raveh, Adi; Diener, Catherine; Fischer, Christophe; Gassmann, Martin; Lindemann, Lothar; Bettler, Bernhard.
Afiliação
  • Werthmann RC; Department of Biomedicine, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland.
  • Tzouros M; Roche Pharmaceutical Research and Early Development, Discovery Neuroscience, Neuroscience and Rare Diseases (NRD) (LL, CD, CF), Pharmaceutical Sciences, Biomarkers, Bioinformatics and Omics & Pathology (MT, JL, AA), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.
  • Lamerz J; Roche Pharmaceutical Research and Early Development, Discovery Neuroscience, Neuroscience and Rare Diseases (NRD) (LL, CD, CF), Pharmaceutical Sciences, Biomarkers, Bioinformatics and Omics & Pathology (MT, JL, AA), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.
  • Augustin A; Roche Pharmaceutical Research and Early Development, Discovery Neuroscience, Neuroscience and Rare Diseases (NRD) (LL, CD, CF), Pharmaceutical Sciences, Biomarkers, Bioinformatics and Omics & Pathology (MT, JL, AA), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.
  • Fritzius T; Department of Biomedicine, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland.
  • Trovò L; Department of Biomedicine, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland.
  • Stawarski M; Department of Biomedicine, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland.
  • Raveh A; Department of Biomedicine, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland.
  • Diener C; Roche Pharmaceutical Research and Early Development, Discovery Neuroscience, Neuroscience and Rare Diseases (NRD) (LL, CD, CF), Pharmaceutical Sciences, Biomarkers, Bioinformatics and Omics & Pathology (MT, JL, AA), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.
  • Fischer C; Roche Pharmaceutical Research and Early Development, Discovery Neuroscience, Neuroscience and Rare Diseases (NRD) (LL, CD, CF), Pharmaceutical Sciences, Biomarkers, Bioinformatics and Omics & Pathology (MT, JL, AA), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.
  • Gassmann M; Department of Biomedicine, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland.
  • Lindemann L; Roche Pharmaceutical Research and Early Development, Discovery Neuroscience, Neuroscience and Rare Diseases (NRD) (LL, CD, CF), Pharmaceutical Sciences, Biomarkers, Bioinformatics and Omics & Pathology (MT, JL, AA), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.
  • Bettler B; Department of Biomedicine, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland. Electronic address: bernhard.bettler@unibas.ch.
Neuropharmacology ; 190: 108426, 2021 06 01.
Article em En | MEDLINE | ID: mdl-33279506
ABSTRACT
For a long time metabotropic glutamate receptors (mGluRs) were thought to regulate neuronal functions as obligatory homodimers. Recent reports, however, indicate the existence of heterodimers between group-II and -III mGluRs in the brain, which differ from the homodimers in their signal transduction and sensitivity to negative allosteric modulators (NAMs). Whether the group-I mGluRs, mGlu1 and mGlu5, form functional heterodimers in the brain is still a matter of debate. We now show that mGlu1 and mGlu5 co-purify from brain membranes and hippocampal tissue and co-localize in cultured hippocampal neurons. Complementation assays with mutants deficient in agonist-binding or G protein-coupling reveal that mGlu1/5 heterodimers are functional in heterologous cells and transfected cultured hippocampal neurons. In contrast to heterodimers between group-II and -III mGluRs, mGlu1/5 receptors exhibit a symmetric signal transduction, with both protomers activating G proteins to a similar extent. NAMs of either protomer in mGlu1/5 receptors partially inhibit signaling, showing that both protomers need to be able to reach an active conformation for full receptor activity. Complete heterodimer inhibition is observed when both protomers are locked in their inactive state by a NAM. In summary, our data show that mGlu1/5 heterodimers exhibit a symmetric signal transduction and thus intermediate signaling efficacy and kinetic properties. Our data support the existence of mGlu1/5 heterodimers in neurons and highlight differences in the signaling transduction of heterodimeric mGluRs that influence allosteric modulation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Glutamato Metabotrópico / Receptor de Glutamato Metabotrópico 5 / Hipocampo / Neurônios Limite: Animals Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Glutamato Metabotrópico / Receptor de Glutamato Metabotrópico 5 / Hipocampo / Neurônios Limite: Animals Idioma: En Ano de publicação: 2021 Tipo de documento: Article